This unique historical oddity says all we need to know about the institution

Mayne Pharma has been awarded $13.2 in legal costs plus interest after the Supreme Court of New South Wales upheld the company in proceedings against Cosette Pharmaceuticals over the US company's attempted termination of the Scheme Implementation Deed signed in early 2025.

Pharmac has proposed switching the brands of meningococcal ACWY, pneumococcal, and influenza vaccines, and widening access to the influenza vaccine so that all children aged 6 months to 5 years could be eligible for funded shots.

A national survey of more than 1,300 Australian general practitioners and practice nurses has revealed a mismatch between the prevalence of age-related muscle loss and its identification in everyday general practice.

In the case of our HTA institution flying close to system perfection, or the sun, patients end up drowning like Icarus. The institution might be Icarus in flight, but patients suffer the consequences if it flies too close to the sun.

The simple fact is that when you refuse to budge on the institution's basic architecture or pricing, or set a clear performance indicator for time-to-funded access, you concede the two obvious levers for delivering what stakeholders want. It explains these consultation processes.

AusBiotech has warned that last week’s 2026-27 Budget offers a mixed bag for Australia’s life sciences sector, with welcome incentives on paper, but proposed changes that risk undermining its future growth.

The Pharmacy Guild of Australia has urged the Albanese government to move quickly to fund diphtheria vaccinations administered in community pharmacies as cases of the disease continue to rise.

At this week’s BPDInsights and BioPharmaDispatch annual conference, Medicines Australia chief Liz de Somer and new GBMA CEO Nikki Lorenz signalled a goal of a united approach to the pending strategic agreement negotiations.

Can we hope that a new First Assistant Secretary to oversee the HTA Review implementation phase will introduce a new way of working and cleanse a process that currently resembles a stagnant pond?

AusBiotech and Tenmile have announced a strategic partnership to support Australia's homegrown life sciences innovation, unveiled by AusBiotech CEO Rebekah Cassidy and Dr Steve Burnell, Managing Director of Tenmile, during the opening address of AusMedtech Day Two.

Lundbeck Australia Managing Director Cara Dignum said, "For nine years, Lundbeck Australia has been recognised for its commitment to building a workplace where employees feel valued, inspired, and connected to the meaningful purpose of serving patients with brain diseases."

Merck and Macquarie University have announced two recipients of the new Merck Indigenous STEM Leadership scholarships funded by the Merck Family Foundation.

Until around 15 years ago, the forecast for spending included nominal annual growth rates of 5-10 per cent, but it was not real. It was not linked to anything. It could not be used to offset new listings because of Budget rules, which remain in place today, and it just made the program a target. It reflects a long-term, enduring dynamic. Nothing will change in the absence of reforming the system's basic architecture.

Cube’s AI Visibility Index Report, presented by Bonnie Leibel at the BPDInsights Conference in Sydney this week, combines market-level benchmarking across 55 pharmaceutical and biotechnology companies operating in Australia.

Australia’s medicine supply chain and pharmacy workforce are under strain, industry leaders warned in a panel discussion at this week's BPDInsights and BioPharmaDispatch annual event.

Australia’s life sciences sector has doubled in size since 2017 and now includes around 3,000 organisations, supporting one in every 65 jobs nationwide.

The BMS leader praised the PBS as a public health program but emphasised that it must be fit for purpose. He said he has respect for what the program represents and that his speech is not an attack on the program, but a defence of what the PBS was designed to be.

Liz Selby, Country Lead for Sanofi Australia and New Zealand, said, "Despite progress in relapsing remitting MS treatments, there remains a significant burden on people with nrSPMS who have limited treatment options to manage their disease progression."

Australia’s growing strength in translational science took centre stage at the second annual Translational Science Hub Symposium in Queensland, where more than 180 researchers, industry leaders and policymakers gathered to highlight how discovery is being turned into real-world patient impact.